These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11374366)

  • 21. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
    Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
    Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
    Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current status of peripheral blood stem cell transplantation: comparison with bone marrow a shematopoietic stem cell graft].
    Mori S; Harada M
    Rinsho Ketsueki; 2002 Feb; 43(2):80-4. PubMed ID: 11925880
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis.
    Ho VT; Mirza NQ; Junco Dd Dd; Okamura T; Przepiorka D
    Bone Marrow Transplant; 2003 Oct; 32(8):771-5. PubMed ID: 14520420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk assessment in haematopoietic stem cell transplantation: stem cell source.
    Urbano-Ispizua A
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):265-80. PubMed ID: 17448961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP
    Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hematopoietic stem cell transplantation].
    Sato N
    Rinsho Byori; 2001 Mar; Suppl 115():103-10. PubMed ID: 11391926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
    Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW; Gorgun G; Miller KB; Foss FM
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
    Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
    J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Allogeneic peripheral blood stem cell transplantation (allo PBSCT) compared with allogeneic bone marrow transplantation (allo BMT)].
    Tanaka J
    Rinsho Ketsueki; 2002 Jun; 43(6):442-6. PubMed ID: 12134697
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation.
    Villaron EM; Almeida J; López-Holgado N; Alcoceba M; Sánchez-Abarca LI; Sanchez-Guijo FM; Alberca M; Pérez-Simon JA; San Miguel JF; Del Cañizo MC
    Haematologica; 2004 Dec; 89(12):1421-7. PubMed ID: 15590390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
    Pollack SM; O'Connor TP; Hashash J; Tabbara IA
    Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.